Nour Heart, Inc.

NOUREXAL

Anti-inflammatories; Cardiovascular treatment preparations; Cardiovascular pharmaceuticals; Prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets, injectables and pharmaceutical preparations for the treatment of cardiovascular disorders; Cardiovascular prevention preparations; Prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets, injectables and pharmaceutical preparations for the prevention of cardiovascular disorders; Pharmaceutical preparations and substances for the treatment of aging and aging-related diseases, as well as viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, Alzheimer, gastrointestinal, hormonal, dermatological, psychiatric, mental depression and immune system related diseases and disorders; Pharmaceutical preparations and substances for the prevention of ischemia-dependent aging and aging-related diseases, including musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, Alzheimer, hormonal, dermatological, psychiatric, mental depression and immune system related diseases and disorders; Neurological Pharmaceuticals; Neurological treatment preparations; Musculoskeletal Pharmaceuticals; Vascular Pharmaceuticals; Pharmaceuticals for Prevention of Ischemic Injury; Pharmaceuticals for Prevention of Disease Progression; Cellular Energy Preservation Pharmaceuticals;

NOURIN

protein arrays for medical diagnosis purposes; gene-based RNA molecular network being RNA sequences for medical diagnosis purposes; protein arrays for diagnosing of heart-related diseases angina, heart attack, cardiac and non-cardiac chest pain, heart failure, cardiovascular diseases, acute coronary syndromes, coronary artery disease, ischemic cardiac disease, subclinical or silent ischemia, low-grade myocardial ischemia, heart transplantation for cardiac allograft inflammation, monitor disease progression, severity of heart damage, risk assessment and prognosis, disease progression, myocardial cell damage, patients at-risk for coronary artery disease, and predict drug therapy response on heart tissue (myocardial cell damage) in clinical trials as well as other diseases, all of the foregoing for medical diagnosis purposes; gene-based RNA molecular network being RNA sequences for diagnosing of heart-related diseases angina, heart attack, cardiac and non-cardiac chest pain, heart failure, cardiovascular diseases, acute coronary syndromes, coronary artery disease, ischemic cardiac disease, subclinical or silent ischemia, low-grade myocardial ischemia, heart transplantation for cardiac allograft inflammation, monitor disease progression, severity of heart damage, risk assessment and prognosis, disease progression, myocardial cell damage, patients at-risk for coronary artery disease, and predict drug therapy response on heart tissue (myocardial cell damage) in clinical trials as well as other diseases, all of the foregoing for medical use; diagnostic biomarker reagents for medical purposes; protein arrays of biomarker reagents for medical diagnosis purposes; gene-based RNA molecular network biomarker reagents for medical diagnosis purposes; protein arrays and gene-based RNA molecular network biomarker reagents for medical diagnosis purposes; tissue-derived diagnostic biomarker reagents for medical purposes; cardiac-derived diagnostic biomarker reagents for medical purposes;protein arrays for research purposes; gene-based RNA molecular network being RNA sequences for research purposes; protein arrays for diagnosing of heart-related diseases angina, heart attack, cardiac and non-cardiac chest pain, heart failure, cardiovascular diseases, acute coronary syndromes, coronary artery disease, ischemic cardiac disease, subclinical or silent ischemia, low-grade myocardial ischemia, heart transplantation for cardiac allograft inflammation, monitor disease progression, severity of heart damage, risk assessment and prognosis, disease progression, myocardial cell damage, patients at-risk for coronary artery disease, and predict drug therapy response on heart tissue (myocardial cell damage) in clinical trials as well as other diseases, all of the foregoing for research purposes; gene-based RNA molecular network being RNA sequences for diagnosing of heart-related diseases angina, heart attack, cardiac and non-cardiac chest pain, heart failure, cardiovascular diseases, acute coronary syndromes, coronary artery disease, ischemic cardiac disease, subclinical or silent ischemia, low-grade myocardial ischemia, heart transplantation for cardiac allograft inflammation, monitor disease progression, severity of heart damage, risk assessment and prognosis, disease progression, myocardial cell damage, patients at-risk for coronary artery disease, and predict drug therapy response on heart tissue (myocardial cell damage) in clinical trials as well as other diseases, all of the foregoing for research use; diagnostic biomarker reagents for research purposes; protein arrays of biomarker reagents for research purposes; gene-based RNA molecular network biomarker reagents for research purposes; protein arrays and gene-based RNA molecular network biomarker reagents for research purposes; tissue-derived diagnostic biomarker reagents for research purposes; cardiac-derived diagnostic biomarker reagents for research purposes;